[an error occurred while processing this directive] | ����Ƥ���Բ�ѧ��־ 2003, 29(2) 117-119 DOI: ISSN: 2096-5540 CN: 32-1880/R | ||||||||||||||||||||||||||||||||||||||||||||||
����Ŀ¼ | ����Ŀ¼ | ������� | ������ [��ӡ��ҳ] [�ر�] | |||||||||||||||||||||||||||||||||||||||||||||||
���� |
| ||||||||||||||||||||||||||||||||||||||||||||||
����10������³�Ա:����20 | |||||||||||||||||||||||||||||||||||||||||||||||
������, ֣�� | |||||||||||||||||||||||||||||||||||||||||||||||
�Ϻ������ҽԺƤ����, 200025 | |||||||||||||||||||||||||||||||||||||||||||||||
ժҪ��
����20��һ���·��ֵ�ϸ������,���ڰ���10����,����Ҫ��������Ƥ��,ͨ����ϸ���������������Խ��,����Ƥ����֢��Ӧ������20��ת����С����ֳ�����������м����֢״������19������24������22�����20�������ǵ�λ�н��淴Ӧ,���Ҳ�ͬ������;���䷴Ӧ�����Ȳ�ͬ�� | |||||||||||||||||||||||||||||||||||||||||||||||
�ؼ����� ����20 ����,����20 ��м�� | |||||||||||||||||||||||||||||||||||||||||||||||
Abstract: | |||||||||||||||||||||||||||||||||||||||||||||||
Keywords: | |||||||||||||||||||||||||||||||||||||||||||||||
�ո����� 2002-05-28 ������ ����淢������ | |||||||||||||||||||||||||||||||||||||||||||||||
DOI: | |||||||||||||||||||||||||||||||||||||||||||||||
������Ŀ:
��������������Ϸ��о��������� (���:CNCS-99M-12) | |||||||||||||||||||||||||||||||||||||||||||||||
ͨѶ����: | |||||||||||||||||||||||||||||||||||||||||||||||
�����: | |||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||
�ο����ף� | |||||||||||||||||||||||||||||||||||||||||||||||
[1] Blumberg H, Conklin D, Xu WF, et al. Interleukin 20:discovery,receptor identification, and role in epidermal function. Cell, 2001, 104(1):9-19. [2] Gallagher G, Dickensheets H, Eskdale J, et al. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun, 2000. 1(7):442-450. [3] Dumoutier L, Louahed J, Renauld JC. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol, 2000, 164(4):1814-1819. [4] Madireddi MT, Dent P, Fisher PB. AP-1 and C/EBP transcription factors contribute to mda-7 gene promoter activity during human mel anoma differentiation. J Cell Physiol, 2000, 185 (1):36-46. [5] Soo C, Shaw WW, Freymiller E, et al. Cutaneous rat wounds express c49a, a novel gene with homology to the human melanoma differentiation associated gene, mda-7. J Cell Biochem, 1999, 74 (1):1-10. [6] Knappe A, Hor S, Wittmann S, et al. Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpesvirus saimiri. J Virol, 2000, 74(8):3881-3887. [7] Liu Y. de Waal Malefyt R, Briere F, et al. The EBV IL-10 homo logue is a selective agonist with impaired binding to the IL-10 receptor. J Immunol. 1997, 158(2):604-613. [8] Beatty PR, Krams SM, Martinez OM. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J Immunol, 1997, 158(9):4045-4051. [9] Kotenko SV. Saccani S, Izotova LS, et al. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc NatlAcad Sci U S A, 2000, 97(4):1695-1700. [10] OFarrell AM, Liu Y, Moore KW, et al. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms:evidence for Stat3-dependent and-independent pathways. EMBO J, 1998. 17 (4):1006-1018. [11] Sano S, Itami S, Takeda K, et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but docs not affect skin morphogenesis. EMBO J. 1999. 18(17):4657-4668. [12] Dumoutier L, Leemans C, Lejeune D, et al. Cutting edge:STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor com plexes of two types. J Immunol, 2001, 167(7):3545-3549 [13] Wang M, Tan Z, Zhang R, et al. Interleukin 24 (MDA-7/MOB 5) signals through two heterodimeric receptors, IL-22R1/IL-20R2and IL-20R1/IL-20R2. J Biol Chem, 2002, 277 (9):7341-7347. [14] Asadullah K, Sterry W, Stephanek K.et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy:a new therapeutic approach. J Clin Invest, 1998, 101(4):783-794. [15] Asadullah K, Docke WD, Ebeling M, et al. Interleukin 10 treatment of psoriasis:clinical.results of a phase 2 trial. Arch Dermatol. 1999. 135(2):187-192. [16] Reich K, Bruck M, Grafe A, et al. Treatment of psoriasis with inter leukin-10. J Invest Dermatol, 1998, 111 (6):1235-1236. [17] Asadullah K, Eskdale J, Wiese A, et al. Interleukin-10 promoter polymorphism in psoriasis. J Invest Dermatol. 2001, 116 (6):975-978. [18] Asadullah K, Prosch S, Audring H, et al. A high prevalence of cyto megalovirus antigenaemia in patients with moderate to severe chronicplaque psoriasis:an association with systemic tunour necrosis factor alpha overexpression. Br J Dermatol, 1999, 141 (1):94-102. [19] Reich K. Mossner R, Konig IR, et al. Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1 bets are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol, 2002, 118 (1):155-163. [20] Kunz M. Henseleit-Walter U, Sorg C, et al. Macrophage marker 27E10 on human keratinocytes helps to differentiate discoid lupus erythematosus and Jessner's lymphocytic infiltration of the skin. Eur J Dermatol. 1999, 9(2):107-110. |
|||||||||||||||||||||||||||||||||||||||||||||||
������������� | |||||||||||||||||||||||||||||||||||||||||||||||
1��������, ����.����20����м��[J]. ����Ƥ���Բ�ѧ��־, 2002,28(5): 283-284 | |||||||||||||||||||||||||||||||||||||||||||||||
�������� (��ע��:��վʵ�������Ը�, �벻Ҫ������ѧ���ص�����!�������ݲ�����վ�۵�.) | |||||||||||||||||||||||||||||||||||||||||||||||
Copyright 2008 by ����Ƥ���Բ�ѧ��־ |